Citigroup
OCUL icon

Citigroup’s Ocular Therapeutix OCUL Stock Holding History

Citigroup’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-17,400
Closed -$77K – 7775
2019
Q2 		$77K Buy
17,400
+2,200
+14% +$8.14K ﹤0.01% 6104
2019
Q1 		$60K Buy
15,200
+4,600
+43% +$18.5K ﹤0.01% 6188
2018
Q4 		$42K Sell
10,600
-11,300
-52% -$62.3K ﹤0.01% 6378
2018
Q3 		$151K Buy
21,900
+19,200
+711% +$120K ﹤0.01% 5516
2018
Q2 		$18K Sell
2,700
-1,700
-39% -$11.7K ﹤0.01% 6974
2018
Q1 		$29K Buy
4,400
+3,100
+238% +$17.4K ﹤0.01% 6529
2017
Q4 		$6K Sell
1,300
-2,900
-69% -$14.8K ﹤0.01% 7189
2017
Q3 		$26K Sell
4,200
-12,400
-75% -$79.8K ﹤0.01% 6341
2017
Q2 		$154K Buy
16,600
+1,800
+12% +$17.4K ﹤0.01% 5007
2017
Q1 		$137K Buy
+14,800
New +$123K ﹤0.01% 4965

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citigroup's OCUL Position: Q1 2026 in Review

Citigroup reduced its Ocular Therapeutix (OCUL) stake by 91% in Q1 2026, selling an estimated $5.21M and leaving 55,777 shares worth $472K. The position accounts for ﹤0.01% of the portfolio, ranked #3583.

Citigroup first reported a position in OCUL in Q3 2014 and has held it in 45 quarters since. The position peaked at $7.87M in Q3 2025. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

  • Citigroup held 55,777 shares of Ocular Therapeutix worth $472K as of Q1 2026.
  • Citigroup sold 546,140 Ocular Therapeutix shares in Q1 2026, an estimated $5.21M.
  • Ocular Therapeutix made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #3583 holding.
  • Citigroup first reported a position in Ocular Therapeutix in Q3 2014 and has held it in 45 quarters since.
  • Citigroup's Ocular Therapeutix position peaked at $7.87M in Q3 2025.
  • 269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.